Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026)

Amarin Corp Plcuk (AMRN) posted quarterly Liabilities and Shareholders Equity of $645.8 million for Q1 2026, down 1.52% YoY from $655.7 million in Q1 2025, and down 3.73% sequentially from $670.8 million in Q4 2025.

Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

Amarin Corp Plcuk has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $645.8 million for Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity fell 1.52% year-over-year to $645.8 million; the TTM figure through Mar 2026 stood at $2.6 billion (down 8.48% YoY), while the FY2025 annual figure was $670.8 million, down 2.13% from the prior year.
  • Liabilities and Shareholders Equity fell to $645.8 million in Q1 2026, from $670.8 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for AMRN reached as high as $973.7 million in Q1 2022 and fell as low as $645.8 million in Q1 2026.
  • The 5-year median for Liabilities and Shareholders Equity is $799.9 million (2024), against an average of $791.8 million.
  • Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity dropped 17.6% — and 2026, when it retreated 1.52%.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $886.2 million in 2022, then decreased by 6.15% to $831.7 million in 2023, then retreated by 17.6% to $685.3 million in 2024, then decreased by 2.13% to $670.8 million in 2025, then retreated by 3.73% to $645.8 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $645.8 million, $670.8 million, and $659.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 116.58 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 200.89 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 136.46 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 114.02 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 128.69 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 92.50 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 56.28 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 208.00 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Amarin Corp Plcuk 5.17 Bn 5.00 Bn 17.77 Mn 645.76 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 645.76 Mn
Dec 31, 2025 670.78 Mn
Sep 30, 2025 659.81 Mn
Jun 30, 2025 670.13 Mn
Mar 31, 2025 655.70 Mn
Dec 31, 2024 685.35 Mn
Sep 30, 2024 750.62 Mn
Jun 30, 2024 799.90 Mn
Mar 31, 2024 790.01 Mn
Dec 31, 2023 831.68 Mn
Sep 30, 2023 839.03 Mn
Jun 30, 2023 860.02 Mn
Mar 31, 2023 860.19 Mn
Dec 31, 2022 886.18 Mn
Sep 30, 2022 908.30 Mn
Jun 30, 2022 973.24 Mn
Mar 31, 2022 973.71 Mn
Dec 31, 2021 1.07 Bn
Sep 30, 2021 1.04 Bn
Jun 30, 2021 1.04 Bn